Hepion Pharmaceuticals, Inc. (HEPA) NASDAQ
0.06
+0.0172(+39.72%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.06
+0.0172(+39.72%)
Currency In USD
| Previous Close | 0.04 |
| Open | 0.05 |
| Day High | 0.07 |
| Day Low | 0.05 |
| 52-Week High | 0.99 |
| 52-Week Low | 0.03 |
| Volume | 74,437 |
| Average Volume | 15,818 |
| Market Cap | 703,029 |
| PE | -0.01 |
| EPS | -9.05 |
| Moving Average 50 Days | 0.05 |
| Moving Average 200 Days | 0.06 |
| Change | 0.02 |
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
GlobeNewswire Inc.
Mar 03, 2026 12:35 PM GMT
Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion’s strategic shift to advancing clinically proven liquid biopsy tests under new leadership MORRISTOWN
Hepion Pharmaceuticals Successfully Completes Application to the OTCQB
GlobeNewswire Inc.
Jun 25, 2025 12:30 PM GMT
MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influ
Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer
GlobeNewswire Inc.
Jun 16, 2025 12:30 PM GMT
MORRISTOWN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTC:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influen